# AstraZeneca PLC Lynparza and Imfinzi Approved in Japan

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-lynparza-imfinzi-approved-japan/412753749
- Published: 2018-07-02T07:57:01+01:00
- Author: Charlotte Edwards

**[AstraZeneca PLC](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MedImmune, its global biologics research and development arm, today announced
that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab)
as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-
advanced (Stage III), unresectable non-small cell lung cancer (NSCLC).

Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit said:“
Non-small cell lung cancer is a leading cause of death in Japan, and we are dedicated
to bringing new treatment options to patients as quickly as possible. As the only
immunotherapy approved in the curative-intent, Stage III lung cancer setting, Imfinzi
has the potential to change the treatment paradigm for patients diagnosed with this
disease.”

The approval of Imfinzi is based on positive progression-free survival (PFS) data
from the Phase III PACIFIC trial in unresectable Stage III NSCLC. In the trial, 
Imfinzi demonstrated an improvement in median PFS of 11.2 months compared to placebo.
Imfinzi improved other meaningful outcomes such as time to distant metastasis or
death and overall response rates. Detailed results of the PACIFIC trial were published
in the New England Journal of Medicine (NEJM).

  |

PFS (first primary endpoint)^(1)

  |

Imfinzi

(N=476)^(2)

  |

Placebo

(N=237)^(2)

  |  
 |

Median in months

(95% CI)

  |

16.8

(13, 18.1)

  |

5.6

(4.6, 7.8)

  |  
 |

Hazard ratio

(95% CI)^(3, 4)

  |

0.52 (0.42, 0.65)

  |  
 |

p-value^(3, 5)

  |

<0.0001

  |

1 Blinded Independent Central Review (BICR).

2 Among the ITT population, 7% in the Imfinzi arm and 10% in the placebo arm had
non-measurable disease as assessed by BICR according to RECIST v1.1.

3 Stratified by sex, age, and smoking history.

4 Pike estimator.

5 Compared with allocated α of 0.0104 (Lan DeMets spending function approximating
O’Brien Fleming boundary) for interim analysis.

The incidence and severity of adverse events were comparable for patients receiving
Imfinzi vs. patients receiving placebo. The most frequent adverse reactions were
rash which occurred in 73 subjects (15.4%), hypothyroidism which occurred in 50 
subjects (10.5%), diarrhoea which occurred in 46 subjects (9.7%) and interstitial
lung disease which occurred in 46 subjects (9.7%).

In May 2018, AstraZeneca announced that the PACIFIC trial met its second primary
endpoint, showing statistically-significant and clinically-meaningful overall survival(
OS) in patients receiving Imfinzi compared to placebo. Full results will be presented
at a forthcoming medical meeting.

Imfinzi is also approved in the US, Canada, Switzerland and India based on the Phase
III PACIFIC trial. Regulatory reviews in the EU and other jurisdictions are ongoing
with an EU decision expected in the second half of 2018.

**AstraZeneca PLC** (LON:AZN)  and Merck & Co., Inc., Kenilworth, N.J., US (Merck:
known as MSD outside the US and Canada) today announced that Japan’s Pharmaceuticals
and Medical Devices Agency (PMDA) has approved Lynparza (olaparib) tablets for use
in patients with unresectable or recurrent BRCA-mutated (BRCAm), human epidermal
growth factor receptor 2 (HER2) negative breast cancer who have received prior chemotherapy.
Patients are selected for therapy based on an approved companion diagnostic.

> **Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit
> at AstraZeneca, said:** “Earlier this year, Lynparza became the first PARP inhibitor
> available in Japan for advanced ovarian cancer. Now patients in Japan with BRCA-
> mutated, metastatic breast cancer will also have the opportunity to benefit from
> Lynparza. This latest approval underlines our ongoing efforts to make Lynparza
> available across multiple cancers as quickly as possible to patients around the
> world.”
> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said:** “Metastatic breast cancer 
> is a complex disease with remaining unmet medical need. This approval is significant
> for breast cancer patients as the evaluation of BRCA mutations, in addition to
> hormone receptor and HER2 status, now becomes an important step in the management
> of the disease.”

The approval is based on data from the randomised, open-label, Phase III OlympiAD
trial, which tested Lynparza vs chemotherapy. Patients were selected for therapy
based upon a confirmed BRCA mutation. In the trial, Lynparza significantly prolonged
progression-free survival (PFS) compared with chemotherapy, reducing the risk of
disease progression or death by 42% (HR 0.58; 95% CI 0.43-0.80; p=0.0009, median
PFS was 7.0 months with Lynparza vs 4.2 months with chemotherapy).

Lynparza was generally well tolerated with the majority of adverse events (AEs) 
reported as mild to moderate with a lower rate of Grade 3 or higher AEs compared
with chemotherapy (36.6% vs 50.5%). The most common AEs were nausea (50.2%), anaemia(
32.2%) and fatigue (22.4%).

Lynparza is also approved in Japan as maintenance treatment for women with platinum-
sensitive relapsed ovarian cancer, regardless of BRCA mutation status. In Japan,
the co-promotion of Lynparza by both companies will begin on 1 July 2018.

Share on:
